The triphenylmethane dye brilliant blue G is only moderately effective at inhibiting amyloid formation by human amylin or at disaggregating amylin amyloid fibrils, but interferes with amyloid assays; Implications for inhibitor design. [PDF]
, 2019 The development of inhibitors of islet amyloid formation is important as pancreatic amyloid deposition contributes to type-2 diabetes and islet transplant failure.
Akter, Rehana +4 more
core +3 more sources
Progress in Neurobiology, 2021 Alcohol causes stimulatory behavioral responses by activating reward-processing brain areas including the laterodorsal (LDTg) and ventral tegmental areas (VTA) and the nucleus accumbens (NAc). Systemic administration of the amylin and calcitonin receptor agonist salmon calcitonin (sCT) attenuates alcohol-mediated behaviors, but the brain sites involved
Kalafateli AL +4 more
openaire +4 more sources
Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]
, 2018 Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen +70 more
core +1 more source
General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. [PDF]
, 2014 Islet amyloid polypeptide (IAPP or amylin) forms amyloid deposits in the islets of Langerhans; a process that is believed to contribute to the progression of type 2 diabetes and to the failure of islet transplants.
Raleigh, David, Wang, Hui
core +2 more sources
Sizing up pharmacotherapy for obesity. [PDF]
, 2010 Obesity has increased over the last 20 years, from a condition affecting only a small portion of populations in developed countries, into a global pandemic.
Terzic, Andre +2 more
core +2 more sources
Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders [PDF]
Clinical and Molecular HepatologyObesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders.
Yun Kyung Cho, Chang Hee Jung
doaj +1 more source
Molecular Metabolism, 2021 Objective: Dual amylin and calcitonin receptor agonists (DACRAs) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to established T2DM therapies.
K.V. Andreassen +5 more
doaj +1 more source
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease [PDF]
, 2009 Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors.
Enrique Z Fisman, Alexander Tenenbaum
core +1 more source
Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics
Acta Pharmaceutica Sinica B, 2022 Diabetes mellitus is a major health problem with increasing prevalence at a global level. The discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the ...
Carlos Bendicho-Lavilla +3 more
doaj +1 more source
Obesity and Appetite Control [PDF]
, 2012 Obesity is one of the major challenges to human health worldwide; however, there are currently no effective pharmacological interventions for obesity.
Bloom, SR, Jayasena, CN, Suzuki, K
core +2 more sources